Operating losses have widened significantly from $10.0 million in 2023Q4 to $27.3 million in 2026Q1, driven by a consistent increase in quarterly R&D spending to $18.5 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 224K | 248K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | -224K | -248K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 98.79M | 98.06M | 68.19M | 35.31M | 25.16M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 23.56M | 18.9M | 10.78M | 6.78M | 3.76M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 75.23M | 79.16M | 57.41M | 28.53M | 21.4M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -98.79M | -98.06M | -68.19M | -35.31M | -25.16M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -43.79% | -93.12% | -40.34% | - |
| EBITDA | -98.56M | -97.81M | -67.95M | -35.15M | -25.11M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | -21.47% | -43.94% | -93.29% | -40.03% | - |
| D&A (Non-Cash Add-back) | 235K | 248K | 244K | 157K | 56K |
| EBIT | -96.48M | -98.06M | -68.19M | -35.31M | -25.76M |
| Net Interest Income | 1.1M | 11.08M | 6.27M | 2.75M | -2K |
| Interest Income | 1.1M | 11.08M | 6.27M | 2.75M | 372K |
| Interest Expense | 0 | 0 | 0 | 0 | 374K |
| Other Income/Expense | 12.18M | 11.08M | 6.27M | 2.75M | -974K |
| Pretax Income | -86.61M | -86.97M | -61.92M | -32.56M | -26.14M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -86.61M | -86.97M | -61.92M | -32.56M | -26.14M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | -17.89% | -40.45% | -90.16% | -24.6% | - |
| Net Income (Continuing) | -86.61M | -86.97M | -61.92M | -32.56M | -26.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.86 | -2.38 | -1.85 | -1.02 | -0.82 |
| EPS Growth % | 0% | -28.65% | -81.37% | -24.39% | - |
| EPS (Basic) | - | -2.38 | -1.85 | -1.02 | -0.82 |
| Diluted Shares Outstanding | 46.58M | 36.51M | 33.39M | 31.85M | 31.85M |
| Basic Shares Outstanding | 46.58M | 36.51M | 33.39M | 31.85M | 31.85M |
| Dividend Payout Ratio | - | - | - | - | - |
Clinical trial execution dependency
As reported in recent financial filings, MBX's quarterly research and development expenses have climbed from $7.7 million in 2023Q4 to $18.5 million by 2026Q1, reflecting the intensified clinical trial activity required to advance the company's proprietary Precision Endocrine Peptide platform through critical mid-stage development milestones.
The consistent upward trajectory in R&D spending underscores the capital-intensive nature of the company's current pipeline progression. Investors should monitor whether this expense growth remains proportional to the clinical de-risking of lead assets or if it signals an unsustainable expansion of the early-stage portfolio.
Based on the company's reported income statements, operating losses have widened significantly from $10.0 million in 2023Q4 to $27.3 million in 2026Q1, indicating that the firm is currently in a phase of heavy investment where overhead and clinical costs far outpace any potential operational efficiencies.
The lack of revenue generation means that operating leverage is currently non-existent, with SG&A expenses also trending upward alongside R&D. This suggests that the company is building out its administrative and operational infrastructure in anticipation of future commercialization, which may place additional pressure on liquidity.
According to quarterly data, stock-based compensation has risen to $5.5 million in 2026Q1, representing a substantial portion of the quarterly net loss and highlighting the reliance on equity-based incentives to attract and retain specialized talent in a highly competitive biotechnology labor market.
The increasing use of stock-based compensation warrants careful investigation, as it effectively masks the true cash cost of operations while simultaneously diluting existing shareholders. Analysts should adjust for these non-cash charges when evaluating the company's true burn rate and long-term capital requirements.
Financial statements indicate that the company's quarterly net loss has consistently hovered near the $20 million to $25 million range, which, when compared against the reported cash position, suggests a limited runway that may necessitate further dilutive financing to reach key clinical data readouts.
Short-term observers might argue that the current cash burn is unsustainable without a strategic partnership or a significant capital raise. The market's valuation of the obesity pipeline may be overly optimistic, potentially ignoring the risk that capital will be diverted away from the core endocrine assets to fund less differentiated programs.
Quick answers to the most common questions about buying MBX stock.
For fiscal year 2025, MBX Biosciences, Inc. Common Stock (MBX) reported total revenue of $0.0M.
MBX Biosciences, Inc. Common Stock (MBX) reported a net loss of $87.0M for the fiscal year ending 2025.